Molina et al. 52 weeks of MANHATTAN study. Guselkumab vs second TNFi after failure 1st TNFi in PsA. MDA 52% vs 33%. Remission/LDA 67% vs 62%. @RheumNow #ACR25 Abstr#2373 https://t.co/qdtOlKLfNU
28-10-2025
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
